Scarica l'app Stockscreener
1.355
12.90%
-0.195
Dopo l'orario di chiusura:
1.41
0.055
+4.06%
Precedente Chiudi:
$1.55
Aprire:
$1.55
Volume 24 ore:
6.48M
Relative Volume:
1.75
Capitalizzazione di mercato:
$359.57M
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-4.8393
EPS:
-0.28
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
-2.17%
1M Prestazione:
-3.57%
6M Prestazione:
-59.34%
1 anno Prestazione:
-36.02%
Intervallo 1D:
$1.33
$1.60
Intervallo di 1 settimana:
$1.33
$1.60
Portata 52W:
$1.30
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.355 | 411.32M | 194.75M | -51.26M | -23.38M | -0.28 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.38 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.63 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.92 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
476.07 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-28 | Iniziato | Leerink Partners | Outperform |
| 2025-04-01 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
AKBA: VAFSEO and pipeline progress drive growth, with major clinical catalysts expected in the next year - TradingView
Akebia Therapeutics Spotlights VAFSEO Dialysis Push, TIW Dosing Plan and Rare Kidney Pipeline at Summit - Yahoo Finance
Loss Report: Can Akebia Therapeutics Inc weather a recessionAnalyst Downgrade & Entry Point Confirmation Alerts - baoquankhu1.vn
Winners Losers: Should I hold or sell Victorias Secret Co now2025 Breakouts & Breakdowns & High Conviction Buy Zone Picks - baoquankhu1.vn
Why The Narrative Around Akebia Therapeutics (AKBA) Is Shifting After New Valuation Reset - Yahoo Finance
Breaking Down Akebia Therapeutics: 4 Analysts Share Their Views - Benzinga
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $4.00 at Piper Sandler - MarketBeat
Piper Sandler Lowers Akebia Therapeutics (AKBA) Price Target to $4.00 | AKBA Stock News - GuruFocus
Akebia Therapeutics (NASDAQ:AKBA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Analyst Reiterates Buy Rating on Akebia Therapeutics (AKBA) with $6 PT | AKBA Stock News - GuruFocus
Akebia Therapeutics (NASDAQ:AKBA) CAO Sells $68,838.36 in Stock - MarketBeat
Akebia Therapeutics to present at Guggenheim Biotech Summit - Traders Union
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Surprises Report: Is Akebia Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Akebia Therapeutics reports inducement grants under Nasdaq listing rule - marketscreener.com
Trading Recap: Will IVCPW benefit from AI trendsWeekly Investment Recap & Accurate Entry/Exit Alerts - baoquankhu1.vn
Earnings Beat: Is Akebia Therapeutics Inc stock showing strong momentumWeekly Market Report & Weekly Return Optimization Alerts - baoquankhu1.vn
Akebia Therapeutics (AKBA): A Potential 272% Upside In The Healthcare Sector - DirectorsTalk Interviews
Akebia Therapeutics signs new headquarters lease and amends executive severance agreements - Investing.com Canada
Akebia Therapeutics announces corporate updates and 2026 pipeline outlook - MSN
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Aug Catalysts: Can Akebia Therapeutics Inc weather a recessionInflation Watch & Reliable Intraday Trade Alerts - baoquankhu1.vn
Income Plays: Whats the beta of Akebia Therapeutics Inc stockQuarterly Trade Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: A 275% Potential Upside That Investors Can't Ignore - DirectorsTalk Interviews
Highs Report: Can Akebia Therapeutics Inc deliver alpha2025 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn
In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions - simplywall.st
Exit Recap: Can Akebia Therapeutics Inc benefit from deglobalizationJuly 2025 Action & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Analyst Calls: What’s the beta of Akebia Therapeutics Inc. stock2025 Retail Activity & Daily Volume Surge Signals - baoquankhu1.vn
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA) - Seeking Alpha
Akebia reports first patient dosed in rare kidney disease trial By Investing.com - Investing.com Nigeria
Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
Akebia (AKBA) Updates on Vafseo and Rare Kidney Disease Pipeline - GuruFocus
Akebia Therapeutics (AKBA) Reports Growth in Vafseo Prescriptions - GuruFocus
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline - TipRanks
Akebia reports first patient dosed in rare kidney disease trial - Investing.com
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook - The Manila Times
Drugmaker maps next steps in Vafseo use and rare kidney disease trials - Stock Titan
How Akebia Therapeutics Inc. stock performs in weak economyJuly 2025 Closing Moves & AI Powered Buy and Sell Recommendations - Улправда
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Unveiling a Potential 262% Upside for Healthcare Investors - DirectorsTalk Interviews
What insider trading reveals about Akebia Therapeutics Inc. stockModel Comparison & HOKA buying tips before checkout - Улправда
How supply chain issues affect Akebia Therapeutics Inc. stock2025 Analyst Calls & Weekly Top Performers Watchlists - Улправда
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Is Akebia Therapeutics Inc. stock affected by interest rate hikesMarket Sentiment Summary & Stock Timing and Entry Methods - ulpravda.ru
How Akebia Therapeutics Inc. (AX9) stock trades pre earningsCPI Data & Trade Opportunity Analysis Reports - Улправда
Can Akebia Therapeutics Inc. stock outperform in 2025 bull market2025 Year in Review & Long-Term Safe Return Strategies - Улправда
Akebia announces first patient dosed in Phase 2 trial of praliciguat - Yahoo Finance
Akebia Therapeutics begins phase 2 trial for rare kidney disease drug - Investing.com Nigeria
Key facts: Akebia starts Phase 2 trial for Praliciguat; grants stock options - TradingView — Track All Markets
Akebia Therapeutics announces first patient dosed in phase 2 clinical trial of praliciguat - marketscreener.com
Akebia Therapeutics begins phase 2 trial for rare kidney disease drug By Investing.com - Investing.com South Africa
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Akebia Therapeutics Inc Azioni (AKBA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Grund Nicholas | Chief Commercial Officer |
Feb 02 '26 |
Sale |
1.39 |
84,829 |
117,912 |
561,750 |
| Burke Steven Keith | SVP, Chief Medical Officer |
Feb 02 '26 |
Sale |
1.39 |
67,658 |
94,045 |
948,432 |
| Rucci Carolyn M. | SVP, Chief Legal Officer |
Feb 02 '26 |
Sale |
1.39 |
69,772 |
96,983 |
588,378 |
| Ostrowski Erik | SVP, CFO, CBO & Treasurer |
Feb 02 '26 |
Sale |
1.39 |
34,951 |
48,582 |
672,635 |
| Butler John P. | CEO and President |
Feb 02 '26 |
Sale |
1.39 |
341,305 |
474,414 |
3,206,233 |
0.53%
10.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):